Vera Therapeutics, Inc. 8-K

What Happened

• On June 2, 2026, Vera Therapeutics, Inc. (VERA) announced in an 8-K that it has aligned with the U.S. Food and Drug Administration on a revised, earlier eGFR analysis plan for its ORIGIN 3 study. The analysis is intended to support potential full approval of atacicept for adults with IgA Nephropathy. The company expects eGFR results in Q3 2026 and, pending those results, plans to submit a supplemental Biologics License Application (BLA) in Q4 2026. The filing was signed by Marshall Fordyce, M.D., Chief Executive Officer.

Key Details

• Filing date: June 2, 2026 (Form 8-K).
• Therapy/indication: atacicept for adults with IgA Nephropathy; analysis from the ORIGIN 3 trial.
• Timeline: eGFR results expected in Q3 2026; supplemental BLA submission planned in Q4 2026.
• Filing includes standard forward-looking statements and risk disclosures.

Why It Matters

• The FDA alignment and an earlier eGFR analysis create clear near-term regulatory milestones (Q3 eGFR readout, potential Q4 BLA submission). These are material events for investors monitoring the company’s path to full approval and potential commercial launch of atacicept.
• The 8-K reiterates forward-looking language and risk factors, so timelines and outcomes are not guaranteed and depend on trial results and regulatory review. Investors should watch the Q3 2026 eGFR data release for updates.